ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: KPT-330 showed remarkable anti-proliferative and pro-apoptotic properties against CML cell lines and patient blasts, including those from patients with BCR-ABL T315I mutation resistant to IM.